Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112

Benzinga · 2d ago
Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and raises the price target from $109 to $112.